NCT04495933View on ClinicalTrials.gov

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
SARS-CoV2Covid19
Interventions
BIOLOGICAL

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg

BIOLOGICAL

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg

BIOLOGICAL

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg

OTHER

Placebo

sterile saline

Trial Locations (1)

4007

Nucleus Network Brisbane (Q-Pharm Pty Ltd), Herston

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

The University of Queensland

OTHER